Hydroxycarbamide solution (Xromi®). HTA ID: 20020

Assessment Status Assessment process complete
HTA ID 20020
Drug Hydroxycarbamide solution
Brand Xromi®
Indication For the prevention of vaso-occlusive complications of sickle cell disease in patients over two years of age.
Assessment Process
Rapid review commissioned 20/04/2020
Rapid review completed 14/05/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that hydroxycarbamide (Xromi®) not be considered for reimbursement at the submitted price.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement; August 2020.